TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related Cancers
TuHURA Biosciences filed an Investigational New Drug (IND) application with the FDA for TBS-2025, a VISTA-inhibiting antibody, targeting molecularly defined subsets of Acute Myeloid Leukemia (AML). The filing follows detailed FDA feedback on a previous submission, with the agency waiving a required meeting in favor of written responses to the proposed Phase 1b/2 development plan.
Key figures
- Drug Name
- TBS-2025
- Phase Of Trial
- Phase 1b/2
- Max dose solid tumor
- 1,000mg every two weeks
- Aml patient subset prevalence
- 60-70%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.